IcoSema vs insulin degludec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
Reported efficacy
Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)
Result source: NCT06269107
insulin degludec · Tresiba
Marketed by Novo Nordisk
NCT00982644 · Phase 3 · completed
The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)
Result source: NCT00982644
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | IcoSema | insulin degludec |
|---|---|---|
| HbA1c, change | -1.6% vs -0.9%vs Insulin IcodecNCT053528152 other results
| -1.1% vs -1.2%vs IGlarNCT0098264422 other results
|
| Body weight, change (kg) | -3.7 vs 2.0vs Insulin IcodecNCT053528151 other result
| 2.9 vs -1vs LiraglutideNCT0260730615 other results
|
| HbA1c below 7% | —Not posted · NCT05013229 | 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116 |
| Fasting plasma glucose, change | -1.9 vs -1.6vs Insulin IcodecNCT053528151 other result
| -4.1 vs -2.6vs LiraglutideNCT0260730615 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05013229 | —Not posted · NCT05802862 |
HbA1c, change
- IcoSema
- -1.6% vs -0.9%vs Insulin IcodecNCT05352815
2 other results
- -1.4% vs -0.9% NCT05259033
- -1.5% vs -1.4% NCT05013229
- insulin degludec
- -1.1% vs -1.2%vs IGlarNCT00982644
22 other results
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.4% vs -1.6% NCT04795531
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.5% vs -1.4% NCT02762578
- -0.1% vs -0.1% NCT03268005
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -1.3% vs -0.4% NCT01676116
- -0.6% vs -0.5% NCT04588259
- -0.1% vs -0.1% NCT01570751
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -0.8% NCT01959529
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- -0.5% vs -0.5% NCT03078478
- -0.9% vs -1.1% NCT00982644
- -0.5% vs 0% NCT04538352
Body weight, change (kg)
- IcoSema
- -3.7 vs 2.0vs Insulin IcodecNCT05352815
1 other result
- 0.9 vs -3.8 NCT05259033
- insulin degludec
- 2.9 vs -1vs LiraglutideNCT02607306
15 other results
- 4.1 vs -1 NCT02607306
- 2.3 vs 2.8 NCT04795531
- 0.2 vs -2.5 NCT03172494
- 0.5 vs 2.2 NCT02501161
- 2.8 vs 2.2 NCT02762578
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- 2.9 vs 1.7 NCT03078478
- 1.2 vs 1.1 NCT03268005
- 1.3 vs -2.5 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 1.2 vs 3 NCT02501161
- -0.7 vs 0.7 NCT02911948
- 2 vs -0.8 NCT01676116
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- IcoSema
- —Not posted · NCT05013229
- insulin degludec
- 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116
Fasting plasma glucose, change
- IcoSema
- -1.9 vs -1.6vs Insulin IcodecNCT05352815
1 other result
- -2.7 vs -1.4 NCT05259033
- insulin degludec
- -4.1 vs -2.6vs LiraglutideNCT02607306
15 other results
- -4.0 vs -2.6 NCT02607306
- -3.0 vs -3.0 NCT04795531
- -3.6 vs -1.9 NCT03172494
- -4.0 vs -3.8 NCT02501161
- -3.0 vs -1.6 NCT02762578
- -3.0 vs -0.6 NCT01676116
- -2.0 vs -1.4 NCT03078478
- 0.6 vs 0.7 NCT03268005
- -3.5 vs -1.9 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -3.9 vs -3.7 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 0.4 vs 0.2 NCT04588259
- -0.8 vs 0 NCT01570751
- -2 vs -4.4 NCT02648217
3-point MACE (% with event)
- IcoSema
- —Not posted · NCT05013229
- insulin degludec
- —Not posted · NCT05802862
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. IcoSema: 6 of 7 rows · insulin degludec: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | IcoSema Rows use multiple source trials | insulin degludec Rows use multiple source trials |
|---|---|---|
| Hypoglycemia Episodes Level 2 event count · count | 15 vs 13 Semaglutide count @ 57wka,b,c NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 23 vs 53 Insulin Icodec count @ 31wka,b,c NCT04795531 · Phase 3 · registry result, not featured evidence |
| Hypoglycemia Episodes Level 2 or 3 event count · count | 15 vs 13 Semaglutide count @ 57wka,b,c NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 25 vs 53 Insulin Icodec count @ 31wka,b,c NCT04795531 · Phase 3 · registry result, not featured evidence |
| Hypoglycemia Episodes Level 3 event count · count | 0 vs 0 Semaglutide count @ 57wka,b,d NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 280 vs 472 Insulin Glargine counta,b,d NCT01959529 · Phase 3 1 other source trial2 vs 0 Insulin Icodec count @ 31wk NCT04795531 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 5.4% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result3.8% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 21.5%once dailye NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results2% NCT01959529 · Phase 3 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence 2.7% NCT04795531 · Phase 3 · registry result, not featured evidence 6.7%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 8.5%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result— NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 2.6%once dailye NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results0% NCT01959529 · Phase 3 —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination — NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence — NCT04795531 · Phase 3 · registry result, not featured evidence 0.6%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence — NCT03268005 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 2.2%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence 0.3%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.2% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 15.1%once dailye NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results38.6% NCT01959529 · Phase 3 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 3.7% NCT03336528 · Phase 4 · registry result, not featured evidence 6.7% NCT04588259 · Phase 3 · registry result, not featured evidence 5.1% NCT04795531 · Phase 3 · registry result, not featured evidence 4%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 20.8% NCT03078478 · Phase 3 · registry result, not featured evidence 7% NCT03268005 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.8%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence —Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination 3.1%Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT01570751 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 23.8% diarrhoea 15.8% vomiting 10.6% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more resultcovid-19 15% nausea 11.7% diarrhoea 11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | once dailye nasopharyngitis 23.9% headache 13.8% diarrhoea 10.8% NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 23 more resultsonce weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination emergency room visit for bilateral knee pain 1.2% emergency room visit for congestive heart failure 1.2% emergency room visit for wound infection 1.2% NCT03336528 · Phase 4 · registry result, not featured evidence diabetic retinopathy 14.7% hyperlipidaemia 14% upper respiratory tract infection 9.3% NCT04588259 · Phase 3 · registry result, not featured evidence covid-19 4.8% influenza 3.1% diabetic retinopathy 2% NCT04795531 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.7% nasopharyngitis 5.1% diabetic retinopathy 3.4% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence nasopharyngitis 19% upper respiratory tract infection 18.1% diarrhoea 9% NCT03078478 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 33.6% weight increased 7% pharyngitis 5.5% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence lipase increased 10% headache 9.3% nasopharyngitis 8.9% NCT01676116 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 1.4% NCT01570751 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 31 weeks versus 57 weeks.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
IcoSema
insulin degludec
+ 105 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · insulin degludec's landscape